BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K. Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: A post hoc analysis of a multicenter study. J Gastroenterol Hepatol 2019;34:364-9. [PMID: 30144366 DOI: 10.1111/jgh.14447] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Yu M, Chen P, Dai C, Hu T, Huang C, Huang Y, Hung C, Lin C, Liu C, Liu C, Peng C, Lin H, Kao J, Chuang W. 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association 2020;119:1135-57. [DOI: 10.1016/j.jfma.2020.04.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
2 Wei L, Kumada H, Perumalswami PV, Tanwandee T, Cheng W, Heo J, Cheng PN, Hwang P, Mu SM, Zhao XM, Asante-Appiah E, Caro L, Hanna GJ, Robertson MN, Haber BA, Talwani R. Safety and efficacy of elbasvir/grazoprevir in Asian participants with hepatitis C virus genotypes 1 and 4 infection. J Gastroenterol Hepatol 2019;34:1597-603. [PMID: 30779220 DOI: 10.1111/jgh.14636] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
3 Smolders EJ, Jansen AME, Ter Horst PGJ, Rockstroh J, Back DJ, Burger DM. Viral Hepatitis C Therapy: Pharmacokinetic and Pharmacodynamic Considerations: A 2019 Update. Clin Pharmacokinet 2019;58:1237-63. [PMID: 31114957 DOI: 10.1007/s40262-019-00774-0] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
4 Nozaki A, Atsukawa M, Kondo C, Toyoda H, Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akahane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S; KTK49 Liver Study Group. The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: a comprehensive analysis of a prospective multicenter study. Hepatol Int 2020;14:225-38. [PMID: 32128704 DOI: 10.1007/s12072-020-10019-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
5 Atsukawa M, Tsubota A, Kondo C, Toyoda H, Nakamuta M, Takaguchi K, Watanabe T, Hiraoka A, Uojima H, Ishikawa T, Iwasa M, Tada T, Nozaki A, Chuma M, Fukunishi S, Asai A, Asano T, Ogawa C, Abe H, Hotta N, Shima T, Iio E, Mikami S, Tachi Y, Fujioka S, Okubo H, Shimada N, Tani J, Hidaka I, Moriya A, Tsuji K, Akahane T, Yamashita N, Okubo T, Arai T, Morita K, Kawata K, Tanaka Y, Okanoue T, Maeda S, Kumada T, Iwakiri K; KTK49 Liver Study Group. Real-World Clinical Application of 12-Week Sofosbuvir/Velpatasvir Treatment for Decompensated Cirrhotic Patients with Genotype 1 and 2: A Prospective, Multicenter Study. Infect Dis Ther 2020;9:851-66. [DOI: 10.1007/s40121-020-00329-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
6 Kawagishi N, Nakamura A, Takayama T, Haga I. Safety of Direct-Acting Antiviral Therapy for Renal Function in Post-Kidney Transplant Patients Infected with Hepatitis C Virus and a 100% 12-Week Sustained Virologic Response: A Single-Center Study. Ther Apher Dial 2020;24:184-8. [PMID: 31290282 DOI: 10.1111/1744-9987.13350] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Fabrizi F, Cerutti R, Messa P. An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease. Pathogens 2021;10:1381. [PMID: 34832537 DOI: 10.3390/pathogens10111381] [Reference Citation Analysis]
8 Atsukawa M, Tsubota A, Kondo C, Uchida-Kobayashi S, Takaguchi K, Tsutsui A, Nozaki A, Chuma M, Hidaka I, Ishikawa T, Iwasa M, Tamai Y, Tobari M, Matsuura K, Nagura Y, Abe H, Kato K, Suzuki K, Okubo T, Arai T, Itokawa N, Toyoda H, Enomoto M, Tamori A, Tanaka Y, Kawada N, Takei Y, Iwakiri K. A novel noninvasive formula for predicting cirrhosis in patients with chronic hepatitis C. PLoS One 2021;16:e0257166. [PMID: 34506563 DOI: 10.1371/journal.pone.0257166] [Reference Citation Analysis]
9 Khaliq S, Raza SM. Current Status of Direct Acting Antiviral Agents against Hepatitis C Virus Infection in Pakistan. Medicina (Kaunas) 2018;54:E80. [PMID: 30400604 DOI: 10.3390/medicina54050080] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
10 Morishita A, Ogawa C, Moriya A, Tani J, Yoneyama H, Fujita K, Oryu M, Senoo T, Takaguchi K, Masaki T. Clinical outcomes of hepatitis C virus elimination using glecaprevir and pibrentasvir in hemodialysis patients: A multicenter study. Hepatol Res 2020;50:557-64. [PMID: 31883211 DOI: 10.1111/hepr.13482] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zarębska‐michaluk D, Jaroszewicz J, Buczyńska I, Simon K, Lorenc B, Tudrujek‐zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Janczewska E, Dybowska D, Halota W, Pawłowska M, Pabjan P, Mazur W, Czauż‐andrzejuk A, Berak H, Horban A, Socha Ł, Klapaczyński J, Piekarska A, Blaszkowska M, Belica‐wdowik T, Dobracka B, Tronina O, Deroń Z, Białkowska‐warzecha J, Laurans Ł, Flisiak R. Real‐world experience with Grazoprevir/Elbasvir in the treatment of previously “difficult to treat” patients infected with hepatitis C virus genotype 1 and 4. Journal of Gastroenterology and Hepatology 2020;35:1238-46. [DOI: 10.1111/jgh.14936] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang SJ, Huang CF, Yu ML. Elbasvir and grazoprevir for the treatment of hepatitis C. Expert Rev Anti Infect Ther 2021;19:1071-81. [PMID: 33428488 DOI: 10.1080/14787210.2021.1874351] [Reference Citation Analysis]
13 Tsai TC, Deng ST, Hsu CW. The efficacy and safety of elbasvir/grazoprevir treatment in HCV genotype 1 patients in Taiwan. J Med Virol 2020;92:219-26. [PMID: 31599455 DOI: 10.1002/jmv.25605] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
14 Miyasaka A, Yoshida Y, Murakami A, Hoshino T, Sawara K, Numao H, Takikawa Y. Safety and efficacy of glecaprevir and pibrentasvir in north Tohoku Japanese patients with genotype 1/2 hepatitis C virus infection. Health Sci Rep 2022;5:e458. [PMID: 35024454 DOI: 10.1002/hsr2.458] [Reference Citation Analysis]